Multimodal RNA drugs to reverse resistance and improve clinical outcomes
Multimodal
We combine the potent binding of high performance aptamer binders with the flexible silencing power of RNAi
Multitargeted
SeekRs™ have the unique ability to target 4 or more pathways with a single agent
Multifunctional
SeekRs™ can be directed to any cell type and can be designed to influence a wide spectrum of cellular funtions and clinical phenotypes
SeekRTM Platform
Pipeline of paradigm
shifting RNA therapies
across multiple indications
OligonTM is pioneering a new class of multimodal and multitargeting RNA therapies to transform outcomes for complex diseases
Leadership
Our Executive Leadership Team
Spyro Mousses, PhD
Founder, Chief Executive Officer and Chairman of the Board
James Silver, LLM
Chief Operating Officer
Andrew Matricaria, MBA
Chief Financial Officer
Culture & Careers
A culture of innovation
We aim to change the clinical status quo by pioneering a new approach to treating complex diseases. Disrupting industries takes tremendous grit, commitment, and courage so we believe in a culture that seeks excellence.